Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
J Allergy Clin Immunol. 2021 Mar; 147(3): 877–878.
Published online 2021 Jan 19. doi: 10.1016/j.jaci.2021.01.004
PMCID: PMC7816615
PMID: 33485650

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

Tiago Azenha Rama, DMD, MD,a,b André Moreira, MD, PhD,a,b,c and Mariana Castells, MD, PhDd

To the Editor:

Mastocytosis encompasses a heterogeneous group of diseases characterized by the presence of clonal mast cells (MCs) in tissues and symptoms of MC activation, including anaphylaxis.1 Vaccination has been shown to cause exacerbation of MC mediator-related symptoms.2 Vaccines against coronavirus disease 2019 (COVID-19) are the solution to the current pandemic, but reports of anaphylaxis following vaccination with the BNT162b2 Pfizer-BioNTech mRNA vaccine have emerged.3 As such, it is important to provide evidence of the safety of mRNA vaccines in populations at risk for anaphylaxis, including patients with mastocytosis and MC activation symptoms.

We report here 2 cases of health care workers with direct contact with patients with COVID-19 and who had a diagnosis of cutaneous and systemic mastocytosis who had successful anti–COVID-19 vaccination. A 37-year-old female nurse with adult-onset monomorphic maculopapular cutaneous mastocytosis lesions, serum basal tryptase level of 12.4 ng/mL with indolent systemic mastocytosis, based on bone marrow MC aggregates with spindle-shape morphology, and negative KIT D816V mutation (World Health Organization major and minor criterion) presented with severe MC mediator-related symptoms including abdominal colicky pain, bloating and diarrhea, generalized pruritus and flare up of lesions, and osteopenia. She received the first dose of the Pfizer-BioNTech mRNA vaccine, BNT162b2, with premedication with H1 and H2 antihistamines, 1 hour before, and montelukast 10 mg, 1 and 24 hours, without side effects. A 47-year-old female nurse with adult-onset monomorphic maculopapular cutaneous mastocytosis, with serum basal tryptase level of 16.2 ng/mL and indolent systemic mastocytosis based on spindle-shaped bone marrow MCs, positive KIT D816V mutation, and MCs expressing CD25 and CD2 (World Health Organization 3 minor criteria) had a history of anaphylaxis with multiple drugs, and MC mediator-related symptoms including migraines, skin pruritus, gastroesophageal reflux, and osteopenia. She received the first dose of the same vaccine, with above premedication, and only had myalgias on the following day.

These 2 cases provide an initial evidence that mRNA COVID-19 vaccines are safe in patients with mastocytosis and MC activation symptoms, including anaphylaxis.

In patients with mastocytosis, the release of MC mediators following vaccination may be related to the activation of Toll-like receptors, noncanonical activation of FcεRI by superantigens bound to IgE, or complement activation.2 , 3 Because the BNT162b2 vaccine contains polyethylene glycol (PEG), a rare cause of IgE-mediated and complement-mediated anaphylaxis, it has been speculated that PEG could be involved in the initial anaphylactic events.3, 4, 5 Although patients with MC activation disorders including mastocytosis are at risk for MC activation and anaphylaxis when exposed to certain drugs and procedures, there is no evidence of increased sensitization or reactivity to PEG. Patients with MC activation disorders may be good candidates for mRNA severe acute respiratory syndrome coronavirus 2 vaccines whenever indicated, with premedication, in an appropriate setting (hospital with available intensive care unit) and under medical surveillance.


We thank the patients for their participation.


Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


1. Brockow K., Jofer C., Behrendt H., Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–232. [PubMed] [Google Scholar]
2. Parente R., Pucino V., Magliacane D., Petraroli A., Loffredo S., Marone G. Evaluation of vaccination safety in children with mastocytosis. Pediatr Allergy Immunol. 2017;28:93–95. [PubMed] [Google Scholar]
3. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines [published online ahead of print December 30, 2020]. N Engl J Med.
4. Stone C.A., Jr., Liu Y., Relling M.V., Krantz M.S., Pratt A.L., Abreo A. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7:1533–1540.e8. [PMC free article] [PubMed] [Google Scholar]
5. Wenande E., Garvey L.H. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907–922. [PubMed] [Google Scholar]